Search Results
Your search for ,maY matches 17054 pages
Showing 11701 - 11750Lung Cancer Alliance Supports Two Young Investigator Awards
The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...
PALOMA-3 Trial in HER2-Negative Metastatic Breast Cancer: Challenge of Moving Beyond Estrogen Receptor Positivity
Hormone receptor–positive breast cancer represents the largest therapeutic subgroup of the disease. The development of endocrine therapies has shaped the treatment paradigm for both advanced- and early-stage disease for decades.1 Still, despite their significant impact, advanced breast cancer...
Learning About Fertility Is Important to Young Patients With Cancer
It is more and more common for people to wait until their 30s or 40s to have children. Consequently, many young adults have not completed their desired childbearing when they are diagnosed with cancer. Cancer treatments can impair fertility directly (usually via gonadotoxicity from chemotherapy,...
Combined-Modality Therapy for Low-Grade Gliomas: Balancing Toxicity, Delivery Logistics, and Survival Benefit
Low-grade gliomas account for 15% of all primary brain tumors and represent a heterogeneous group of glial neoplasms. Although these tumors have been termed low-grade, this is a misnomer, especially for some grade II gliomas, which may exhibit a more aggressive behavior and variable natural...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
ASCO Clinical Practice Guideline Update on Ovarian Suppression/Adjuvant Endocrine Therapy in Hormone Receptor–Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues, ASCO has released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone...
Nivolumab in Classical Hodgkin Lymphoma
On May 17, 2016, nivolumab (Opdivo) was granted accelerated approval for treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (Adcetris).1,2 Continued approval for ...
PD-L1 Inhibitor Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.On May 18, 2016, the PD-L1 (programmed cell death ligand 1)...
ASCO Applauds the FDA for Regulating E-Cigarettes
ASCO President Julie M. Vose, MD, MBA, FASCO, issued the following statement in response to the U.S. Food and Drug Administration’s (FDA) move to regulate electronic cigarettes. “ASCO applauds the FDA for exercising its congressionally mandated authority to regulate cigars, hookah tobacco,...
Statement From FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
On June 2, 2016, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement on the release of the final individual patient expanded access form. “Today, the FDA finalized its efforts to streamline the process used by physicians to request expanded...
Atezolizumab in Platinum-Treated Advanced Urothelial Carcinoma: A New Standard of Care?
Compared with a historic control rate, a phase II study of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) has demonstrated clinically meaningful responses in patients with urothelial carcinoma who progressed after platinum-based chemotherapy.1 Hailed as a “major...
Providing Inpatient Physical Rehabilitation for Patients With Advanced Cancer
Guest Editor Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is guest edited by Sean Smith, ...
Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients
A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...
Moving the Needle on HPV Vaccination
In 2012–2013, members of the President’s Cancer Panel (prescancerpanel.cancer.gov) focused their efforts on accelerating widespread acceptance of and use of approved human papillomavirus (HPV) vaccines to prevent cancer. The topic is important, because HPVs cause most cases of cervical cancer and...
University of Catania Presents Margaret Foti Scholar-in-Training Award to Saverio Candido, PhD
The American Association for Cancer Research (AACR) congratulates Saverio Candido, PhD, on receiving the fourth Margaret Foti Scholar-in-Training Award from the University of Catania in Italy. Dr. Candido is being recognized for his research on biomarkers of bladder cancer development and...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Howard H. Bailey, MD, of the University of Wisconsin Carbone Cancer Center, and colleagues, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States.1 In the United...
It Started With Twitter: ASBrS Immediate Past-President, Deanna Attai, MD, Spearheads Patient-Centered Care
Breast surgeon Deanna Attai, MD, is a virtual mighty mouse as a spokesperson for her professional organization, the American Society of Breast Surgeons (ASBrS). She is as big on ideas as she is petite in stature and for actively tweeting on medical topics (@DrAttai). Assistant Clinical Professor...
Increased Risk of Gallbladder Cancer May Be Linked to Consuming Large Amounts of Sweetened Beverages
A large prospective Swedish study reported by Larsson et al found a 2.2-fold increased risk of gallbladder cancer in people who consumed two or more servings of sweetened beverages a day compared with nonconsumers. The researchers also found a 1.8-fold increase in extrahepatic biliary tract cancer...
How Will Value Framework Tools Be Used in Everyday Practice?
Value framework tools made a splash in 2015, with five different groups unveiling methods to help physicians and patients compare therapies based on efficacy, toxicity, and/or cost. Now these potential users are beginning to examine and debate the tools, including how and whether they will work in...
Adjuvant Chemotherapy Improves Survival in Pancreatic Cancer
An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting.1 The combination of gemcitabine and capecitabine almost doubled the 5-year survival rate, compared to...
Chemoradiotherapy Improves Survival in Patients Over Age 65 With Glioblastoma: A New Standard Option?
The combination of short-course radiotherapy and temozolomide followed by maintenance with temozolomide significantly improved survival compared with short-course radiotherapy alone in newly diagnosed elderly patients with glioblastoma, according to the results of a global cooperative group trial...
ASCO Urges Centers for Medicare & Medicaid Services to Withdraw Medicare Part B Demo in Formal Comments
ASCO President Julie M. Vose, MD, MBA, FASCO, issued this statement on May 10. “In comments1 submitted yesterday to the Centers for Medicare & Medicaid Services (CMS), ASCO underscored the urgent need to advance a more fair and responsible payment system for oncology than what is proposed in...
Rising Breast Cancer Incidence in Sub-Saharan Africa: Challenges and Opportunities
The incidence of new cases of breast cancer in low- and middle-income countries, particularly in sub-Saharan Africa, is rising, and it will take a concerted effort from the international cancer community to counteract this troubling upward trend. It has been estimated that of the 15 million cancer ...
Expert Point of View: Harold J. Burstein, MD, and Ian Smith, MD
“There is a tremendous interest in longer aromatase inhibitor therapy. The Oxford Overview data, presented at ASCO, show the substantial risk of recurrence in years 5 to 15, despite an initial 5 years of adjuvant endocrine treatment. “Women with lower-risk breast cancer will be less inclined to...
Jeffrey Sosman, MD, Joins Northwestern’s Lurie Comprehensive Cancer Center
Jeffrey Sosman, MD, melanoma expert and researcher, will join the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as Co-Leader of the Translational Research in Solid Tumors (TRIST) Program and Director of the Melanoma Program. He will also serve as Director for Faculty...
Additional 5 Years of Letrozole May Benefit Some Postmenopausal Women With Early-Stage Breast Cancer
Five years of aromatase inhibitor as upfront therapy or after tamoxifen is the current standard of care for postmenopausal women with early hormone receptor–positive breast cancer. A new trial suggests that extending aromatase inhibitor therapy with letrozole for an additional 5 years may improve...
The ENDEAVOR Trial: A Case Study in the Interpretation of Modern Cancer Trials
It can be easy to miss the forest for the trees in the interpretation of clinical trials. In particular, trials for the treatment of cancer are exceedingly complex, with long lists of inclusion and exclusion criteria, designs with hidden biases, drugs with unpronounceable names (if not cumbersome...
Global Economic Crisis May Be Linked to Increased Cancer Mortality
The global economic crisis has been associated with increased unemployment and reduced public-sector expenditure on health care. In a study reported in The Lancet, Maruthappu et al found that the global economic crisis beginning in 2008 was also associated with a large excess in cancer mortality...
Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease
In a study reported in the Journal of Clinical Oncology, Yu et al identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery Cohort In the study, a quantitative proteomics approach was used to compare...
Enzastaurin Fails to Improve Outcomes in Patients With High-Risk DLBCL in Remission After Chemotherapy
Crump et al found no disease-free survival benefit of maintenance therapy with the selective protein kinase Cb (PKCb) inhibitor enzastaurin in patients with diffuse large B-cell lymphoma (DLBCL) who were in complete remission and at high risk of relapse after first-line chemotherapy, according to a ...
ASCO 2016: Significant Cost Differences Found Among Breast Cancer Chemotherapy Regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new research from The University of Texas MD Anderson Cancer Center. Understanding cost differences should help guide informed discussions between patients and...
ASCO 2016: Local Consolidative Therapy Improves Progression-Free Survival in Patients With Oligometastatic NSCLC vs Standard Chemotherapy
Lung cancer patients with oligometastases, defined as three or fewer sites of metastasis, may benefit from aggressive local therapy, surgery, or radiation, after standard chemotherapy, according to research led by The University of Texas MD Anderson Cancer Center. If validated in larger studies,...
ASCO 2016: Nivolumab Immunotherapy Improves Survival, Quality of Life in Metastatic or Recurrent Head and Neck Cancer
Treatment with nivolumab (Opdivo) doubled overall survival and improved quality of life, with fewer side effects, in a treatment-resistant and rapidly progressing form of head and neck carcinoma, reported a large, randomized international trial co-led by investigators at the University of...
Investigational Drug Abemaciclib Shows Promising Activity Against Several Cancer Types in Early Study
An experimental CDK inhibitor, abemaciclib, yielded encouraging and durable results against several different types of cancers, including breast cancer, lung cancer, glioblastoma, and melanoma, according to a report published by Patnaik et al in Cancer Discovery. The results of the trial supported ...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma
James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).
ASCO 2016: Vast Differences Globally in Cancer Drug Retail Prices
A pilot study revealed large differences in median retail prices for 23 cancer drugs in 7 different countries, with the highest retail prices identified in the United States and the lowest, in India and South Africa. Notably, after the monthly drug price is expressed as a percentage of domestic...
ASCO 2016: Minority BRCA-Positive Breast Cancer Survivors Appear Less Likely to Receive Preventive Surgery
For breast cancer survivors who carry mutations in BRCA genes, preventive surgery may substantially reduce the risk of future breast and ovarian cancers. However, it appears that black women are far less likely to receive these widely recommended procedures than white or Hispanic...
ASCO 2016: Many Younger Cancer Patients Receive Aggressive End-of-Life Care Despite ASCO’s Choosing Wisely Campaign
An analysis of health claims data from 2007–2014 on more than 28,000 patients under the age of 65 found that a large proportion of patients with advanced solid tumors received at least one form of aggressive care within the last 30 days of life. The study was presented by Chen et al at...
ASCO 2016: Novel Antibody Significantly Improves Survival in Patients With Advanced Gastric Cancer
Findings from the European phase II FAST study showed that the novel, first-in-class antibody IMAB362 can significantly extend median survival when added to standard chemotherapy (13.2 vs 8.4 months) for patients with advanced gastric cancer. This therapy targets a protein called claudin-18 splice...
ASCO 2016: Atezolizumab Benefits Patients With Advanced Bladder Cancer
The anti–programmed cell death ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq) is effective in patients with previously untreated advanced bladder cancer who are not eligible for the standard treatment with cisplatin. According to a nonrandomized phase II trial, atezolizumab shrank...
ASCO 2016: New Antibody-Drug Conjugate Shows Early Promise in Small Cell Lung Cancer
Early findings from a first-in-human clinical trial showed that the antibody-drug conjugate rovalpituzumab tesirine (Rova-T) shows promising efficacy against recurrent small cell lung cancer (SCLC). The treatment, which combines a novel anti-DLL3 antibody with a powerful anticancer agent, halted...
Usha Menon, MD, on Ovarian Cancer: Advances in Early Detection
Usha Menon, MD, of University College London, discusses a significant new version of a screening test for ovarian cancer that may reduce death from the disease (Abstract 5507).
ASCO 2016: Rucaparib Shows Clinical Benefit in BRCA-Mutated Pancreatic Cancer
The targeted PARP inhibitor rucaparib, which has demonstrated robust clinical activity in patients with ovarian cancer who have a BRCA mutation, also showed promise in previously treated patients with pancreatic cancer who have the mutation, according to results from a phase II clinical study...
ASCO 2016: Innovative Direct-to-Patient Outreach May Accelerate Breast Cancer Research
An innovative project launched in October 2015 may help expedite metastatic breast cancer genomics research and provide leads for development of new treatments. In the 7 months since the launch, more than 2,000 patients have enrolled in the research study designed to collect and...
ASCO 2016: Liquid Biopsy May Help Guide Treatment Decisions for Patients With Advanced Solid Tumors
A large-scale genomic analysis found that patterns of genetic changes detected in blood samples (liquid biopsy) closely mirror those identified in traditional tumor biopsy. With blood samples from more than 15,000 patients and 50 different tumor types, this is one of the largest cancer genomics...
ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients
Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
For a more in-depth look at these data, as well as commentary, click here. A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. Adjuvant...
ASCO 2016: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer
A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study. The response rates were comparable among women who received trastuzumab and among...
ASCO 2016: Adding Intraperitoneal Chemotherapy to Intravenous Chemotherapy Slows Ovarian Cancer Progression
For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy intraperitoneally as well as intravenously appears more effective than intravenous chemotherapy alone. For women who were initially treated with chemotherapy prior to surgery, the ...
